{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-026668","form_type":"8-K","ticker":"CBLL","cik":"0001861107","company_name":"Ceribell, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.360612+00:00","generated_at":"2026-05-26T04:58:13.812916+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ceribell Q4 revenue $18.5M (+41% YoY); FY2024 revenue $65.4M (+45%); guides FY2025 $81-85M","bullets":["Q4 revenue $18.5M (+41% YoY); product $14.1M, subscription $4.4M; gross margin 88%.","FY2024 revenue $65.4M (+45%); net loss $40.5M ($3.39/share) vs $29.5M ($5.56/share) in 2023.","Cash and equivalents $194.4M at Dec 31, 2024; active accounts 529; over 200,000 patients treated.","FY2025 revenue guidance $81-85M, representing 24-30% growth over FY2024.","Submitted 510(k) for pediatric Clarity algorithm; Sean Manni promoted to Chief Revenue Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-026668","json":"https://secwatch.observer/filing/0000950170-25-026668.json","markdown":"https://secwatch.observer/filing/0000950170-25-026668.md","text":"https://secwatch.observer/filing/0000950170-25-026668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861107/000095017025026668/0000950170-25-026668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861107/000095017025026668/cbll-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:58:13.812916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}